The resignation of FDA Commissioner Marty Makary on May 12, 2026, effectively unblocked the administrative queue for scheduling critical drug and device advisory meetings. This shift signals a broader effort to revitalize a system that has long been the backbone of regulatory transparency. The
Prohibiting management services organizations from owning equity or financing physician ownership could force a massive restructuring of the current healthcare investment market. Launched in late 2026, the Stop Corporate Takeovers of Physicians Act serves as a definitive federal intervention into
A core-and-spoke staffing model allows growing biotech firms to maintain deep expertise in niche regulatory areas while keeping internal overhead costs manageable. This approach is particularly effective in an era where the line between laboratory innovation and regulatory scrutiny has become
A comparative study using a trastuzumab biosimilar revealed that automation can reduce the average variability in glycan profiling by twenty-eight percent compared to manual processing. This discovery comes at a critical time in 2026, as the pharmaceutical sector grapples with the increasing
A gross margin expansion to 72.8% in the second quarter of 2026 demonstrated iRhythm's operational scaling just as a significant cybersecurity crisis unfolded. The intersection of these two events creates a paradox for the digital healthcare giant, which has seen its Zio platform achieve
BeneMeat’s partnership with the Italian brand FORZA10 serves as a practical case study for the commercial application of cultivated cells in the animal feed sector. This collaboration marks a significant milestone in the broader trajectory of cellular agriculture, moving beyond speculative research
